While human clinical trials directly measuring cortisol changes during GLP-1 therapy remain limited, the receptor distribution and mechanistic evidence support a plausible link between these medications and improved stress hormone regulation
Staying hydrated is especially important if nausea occurs, and patients should eat smaller, more frequent meals to minimize gastrointestinal discomfort
GLP-1R agonists such as semaglutide (Ozempic), liraglutide (Victoza), and dulaglutide (Trulicity) are best known for enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner
FDA Submission Timeline Based on the TRIUMPH-4 success and expected 2026 readouts, analysts predict: Late 2026: Completion of core TRIUMPH trials Q4 2026 or Q1 2027: New Drug Application (NDA) submission to FDA Mid to Late 2027: Potential FDA approval Early 2028: Commercial launch Eli Lilly has not officially confirmed these timelines, but the company has indicated it will submit for regulatory approval once sufficient Phase 3 data is available
They are the bare minimum for injectable medication safety
